RYAM (RYAM) Q2 2025: Tariff and Ops Headwinds Total $51M, Margin Expansion Path Reaffirmed
RYAM’s Q2 revealed a combined $51 million EBITDA drag from tariffs and operational disruptions, but management projects these headwinds are now receding and expects a return to margin expansion by 2026. With a $35 million turnaround plan for Tumiskaming and $30 million in structural cost reductions underway, RYAM is positioning for a core EBITDA run rate over $300 million by 2027, fueled by cellular specialties and biomaterials. Strategic asset divestitures, disciplined capital allocation, and new product launches underpin a multi-year transformation, though execution risk remains as the company pivots from recovery to growth.
Summary
- Tariff Disruption Reverses: Major tariff headwinds are abating, shifting to a potential tailwind for U.S. exports.
- Cost and Asset Restructuring: Tumiskaming turnaround and automation-driven cost cuts anchor the margin recovery thesis.
- Biomaterials Growth Pipeline: Multi-year bio-based projects target high-ROI returns, leveraging existing infrastructure.
Performance Analysis
RYAM’s Q2 results were marked by substantial year-over-year declines across all major business segments, reflecting the acute impact of tariffs, labor disruptions, and operational challenges. Cellulose specialties (CS), the company’s core segment, saw net sales drop $33 million on a 15 percent volume decline, with EBITDA margins compressing to 22 percent from 28 percent a year ago. The paperboard and high-yield pulp businesses also posted double-digit sales and margin declines, with paperboard margins halving to 11 percent and high-yield pulp swinging to a larger operating loss, underscoring the sensitivity of non-core assets to macro and trade volatility.
Operationally, RYAM absorbed $18 million in EBITDA headwinds from labor strikes, weather, and outages, with a further $21 million drag attributed to direct and indirect tariff disruptions. Foreign exchange added another $8 million in short-term pressure, though management now views the weaker dollar as a longer-term cost advantage. Despite these setbacks, the company maintained liquidity of $202 million and is guiding for a notable second-half EBITDA rebound, banking on normalization of trade flows and the resolution of one-off operational issues.
- Volume Sensitivity: The 15 percent CS volume decline drove most of the segment’s $22 million EBITDA drop, exposing the business to order volatility from trade policy swings.
- Paperboard Drag: Tumiskaming’s breakeven-to-slight-loss outlook and custodial costs highlight the urgency of the $35 million turnaround plan and eventual divestiture.
- Cash Flow Inflection: Management projects positive free cash flow in the second half, reversing a $52 million outflow year-to-date as headwinds subside.
The quarter’s results reinforce that while RYAM’s core business is structurally advantaged, near-term execution and market normalization are critical to realizing the longer-term EBITDA and margin expansion targets.
Executive Commentary
"The tariff story, which clearly a headwind in 2025, is showing strong indications of turning into a potential strategic advantage for us moving forward. However, we are not incorporating any of these potential tailwinds in our outlook."
Delisle Blomquist, Chief Executive Officer
"Adjusted free cash flow year to date was negative $52 million, while adjusted EBITDA was $28 million, a $40 million decrease compared to the second quarter of last year... Given these results, we have revised our full year 2025 adjusted EBITDA guidance to a range of $150 million to $160 million."
Marcus, Chief Financial Officer
Strategic Positioning
1. Core Focus: Cellular Specialties Margin Expansion
RYAM’s strategic pivot centers on cellular specialties (CS), a high-purity wood pulp used in filtration, food, and specialty chemical applications. Management is leveraging industry consolidation, with RYAM and two peers controlling 80 percent of global CS capacity, to pursue pricing power and margin recovery. Secular demand growth of 4 to 6 percent annually and limited new capacity support a thesis of stable price increases outpacing cost inflation. The company is also targeting $30 million in incremental CS EBITDA by 2027, driven by volume substitution from commodity pulp and price realization.
2. Tumiskaming Turnaround and Divestiture
The Tumiskaming paperboard and high-yield pulp assets, currently a drag on group results, are the focus of a $35 million EBITDA restoration plan featuring cost cuts, automation, and new product launches (freezer board, oil and grease resistant board, and high-yield softwood rolls). Management aims to return the asset to historical $30 million EBITDA levels, positioning it for divestiture at a 5-7x mid-cycle multiple, which could unlock $180 million in proceeds for debt paydown or reinvestment.
3. Biomaterials Pipeline: High-ROI Growth
RYAM is investing in a multi-year biomaterials strategy, repurposing byproducts from its pulp operations into high-value products such as bioethanol, crude tall oil, prebiotics, and biogenic CO2 for sustainable aviation fuel. The Tardis bioethanol plant, backed by a take-or-pay contract with ExxonMobil, exemplifies this approach, generating $8-10 million EBITDA on a $5 million equity outlay. The Bionova joint venture and the Ultimaha Green Energy (AGE) project further expand this pipeline, with a combined $110 million in capital targeting $39 million annual EBITDA and equity returns of 7-12x, leveraging RYAM’s existing asset base for cost advantage.
4. Cost Structure Overhaul
Structural cost reduction is a core pillar, with a $30 million annual savings target by 2026 (via $24 million capital spend in 2025). Initiatives include automation, ERP-driven efficiency, and reduced energy and material usage. These savings are expected to provide durable margin expansion, with additional projects in the pipeline for 2027 and beyond.
5. Balance Sheet and Capital Allocation Discipline
RYAM’s $202 million liquidity and sub-covenant leverage provide flexibility to fund growth internally, avoiding shareholder dilution. The upcoming callability of term debt in 2026 presents a $40 million annual interest savings opportunity, contingent on asset sale proceeds. Management’s capital allocation prioritizes high-ROI projects and measured debt reduction, with shareholder returns a longer-term consideration.
Key Considerations
RYAM’s Q2 marked a transition from crisis management to recovery mode, with several levers in play to restore profitability and unlock value. Strategic execution on cost, product, and asset initiatives will determine the pace and magnitude of the margin expansion and growth thesis.
Key Considerations:
- Tariff Dynamics Shift: Recent U.S. tariffs on EU and Brazil imports create a competitive moat for RYAM, but require effective market share capture and price discipline.
- Execution Risk on Turnarounds: The Tumiskaming plan and new product launches must deliver on schedule to restore segment profitability and enable divestiture.
- Biomaterials Commercialization: Success in ramping up bio-based projects hinges on timely permitting, engineering, and securing offtake contracts, with commercial agreements required before capital deployment.
- Cost Reduction Delivery: Achieving the $30 million run-rate savings by 2026 is critical to offsetting inflation and restoring margins, with most investments frontloaded in 2025.
- Capital Allocation Balance: Management’s focus is on high-return internal projects and measured debt paydown, with shareholder returns only likely once the project pipeline matures.
Risks
Execution on multiple simultaneous initiatives, including cost savings, product launches, and asset divestitures, presents operational and timing risk. Tariff policy, while currently favorable, remains subject to geopolitical shifts. The biomaterials pipeline, though validated by market contracts, could face permitting, ramp, or market adoption delays. Macro headwinds in construction and industrial end markets may further dampen cyclical demand recovery, particularly in Europe and China.
Forward Outlook
For Q3 and Q4 2025, RYAM guided to:
- Second-half adjusted EBITDA of $105 million to $115 million, reflecting normalization of trade flows and recovery from operational disruptions.
- Positive free cash flow of approximately $35 million in the second half, reversing year-to-date outflows.
For full-year 2025, management revised guidance to:
- Adjusted EBITDA of $150 million to $160 million.
- Adjusted free cash flow of negative $10 million to $25 million.
Management emphasized no upside from potential tariff tailwinds is included in the forecast, and that 2026 will see the full run-rate benefit from cost reduction and new product initiatives.
- 2026: Full realization of $30 million cost savings and Tumiskaming product launches
- 2027: Core EBITDA run rate targeted at $308 million, with further upside from biomaterials projects
Takeaways
RYAM’s Q2 was a trough quarter, but management’s roadmap to margin expansion and growth is intact—execution is now the gating factor.
- Tariff and FX Headwinds Fade: Direct and indirect tariff impacts totaling $21 million, plus $8 million FX drag, are not expected to recur, setting the stage for recovery.
- Multi-Pronged Margin Expansion: Cost reductions, asset divestiture, and biomaterials commercialization underpin a credible path to over $300 million core EBITDA by 2027, contingent on timely delivery.
- Watch for Turnaround Proof Points: Investors should monitor Tumiskaming’s product ramp, CS volume recovery, and biomaterials project FIDs as leading indicators of execution and value unlock.
Conclusion
RYAM’s Q2 underscored the magnitude of recent headwinds, but with most disruptions behind it, the company’s focus shifts to delivering on a well-defined margin and growth agenda. Strategic asset optimization, disciplined capital allocation, and a robust biomaterials pipeline provide the levers for sustainable value creation—if execution matches ambition.
Industry Read-Through
RYAM’s experience highlights the volatility that trade policy and operational disruptions can impose on specialty pulp and paper producers, with tariffs capable of swinging segment margins by tens of millions. The pivot to biomaterials and value-added byproducts is increasingly central for pulp players seeking higher returns and less cyclicality, mirroring broader trends in the global forest products sector. Industry peers with excess capacity or exposure to commodity pulp face similar imperatives to rationalize assets and invest in higher-margin, sustainable growth adjacencies. For investors, the sector’s near-term volatility masks significant optionality for operators able to execute on cost, product, and capital strategies in a consolidating market.